ArticleEBioMedicine2026
Liver disease reveals KIF12 as a regulator of mitochondria, lysosome and cilia localisation in human cholangiocytes.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic testing in liver diseases: Clinical applications.JHEP reports : innovation in hepatology · 2026Review
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
backgroundRare bi-allelic mutations in kinesin family member 12 (KIF12) cause high gamma-glutamyl transferase (GGT) cholestatic liver disease, yet the cellular mechanisms driving this phenotype remain unknown.
methodsTo investigate the role of KIF12 in biliary pathology, we introduced the homozygous p.Arg219∗ KIF12 mutation, previously identified in affected patients, into induced pluripotent stem cells (iPSCs). These cells were differentiated into 2D human cholangiocyte-like cells (iCCs) and 3D biliary organoids.
findingsAnalysis of healthy human liver single cell RNA-sequencing datasets demonstrated that KIF12 is primarily detected in biliary epithelial cells. Pioneering single-molecule fluorescence microscopy in live iCCs, we observed wildtype KIF12 co-localising with microtubules, supporting its predicted function as a microtubule-associated motor protein. The p.Arg219∗ variant was associated with reduced KIF12 transcript abundance and markedly reduced detectable tagged mutant protein in an overexpression system. Mutant iCCs exhibited abnormal perinuclear clustering of mitochondria and lysosomes, mislocalisation of primary cilia, and increased GGT activity, all of which were rescued by re-expression of wildtype KIF12.
interpretationThis study identifies KIF12 as a key regulator of organelle localisation in human cholangiocytes, expanding our understanding of kinesin roles beyond their established functions in neuronal systems. Our findings provide new insights into the pathogenesis of KIF12-related cholestatic liver disease and establish a foundation for developing targeted genetic therapies.
fundingThis study was supported by Doris Duke Charitable Foundation, the National Institutes of Health and internal funds from the Center for Transcriptional Medicine at the University of Pittsburgh.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.